Cave rescue

Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook

Retrieved on: 
Monday, January 29, 2024
Biometrics, Radiology, Biotechnology, Oncology, Health, Medical Devices, Health Technology, Clinical Trials, Mortality, ChromeOS, Bank statement, Lung cancer screening, HCC, Patient, Machine learning, Imaging, Artificial intelligence, REALITY, Partnership, Cave rescue, COVID-19, MRMC, Stand-alone, ESMO, AI, Lung cancer, Big Pharma, Growth, LCS, Hepatocellular carcinoma, Medical device, AUC, Acceleration, EIB, Small Business Saturday, Hospital, FDA, BofA Securities, Diagnosis, CE, European Investment Bank, Fine chemical

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.
  • Fredrik Brag, Chief Executive Officer and Founder of Median Technologies, commented: "In Q4 2023, our iCRO1 business achieved record-high order intake, which increased significantly our backlog.
  • We expect to return to growth in 2024 on the back of a decline in 2023 revenue due to soft order intake in China caused by the Covid lockdowns in 2022 and H1 2023."
  • The Standalone study will be finalized in Q2 2024 and the MRMC study in Q3 2024.

Median Technologies to Speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 - 30, Chicago, IL, USA

Retrieved on: 
Wednesday, November 22, 2023
Software, Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Medical Devices, Technology, RSNA, AI, Cave rescue, Exhibition

Median Technologies (ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the Radiological Society of North America (RSNA) 2023 Annual Meeting and Scientific Assembly, being held in Chicago, IL, USA, Nov. 26-30, 2023.

Key Points: 
  • Median Technologies (ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the Radiological Society of North America (RSNA) 2023 Annual Meeting and Scientific Assembly, being held in Chicago, IL, USA, Nov. 26-30, 2023.
  • The Company will give a presentation.
  • Details of the session include:
    Median’s iBiopsy® and iCRO teams will be available at booth #4465, Level 3 South Hall (AI showcase) for the duration of the industry exhibition (Nov 26- 29, 10:00 am – 5:00 pm CT).

Median Technologies Reports 2023 Half-year Results and Business Indicators for the Third Quarter of 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Technology, Health, Radiology, Oncology, Medical Devices, Research, Artificial Intelligence, Surgery, Science, Clinical Trials, Survival, FDA, LP, NMPA, Medical device, Q2, Lung cancer, Medicine, Mortality, US Foods, Chinese, Software, Euronext Growth, Q3, Business, Cave rescue, Survival rate, Patient, EIB, Diagnosis, LCS, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Median

Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).

Key Points: 
  • Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).
  • Commenting on the results, Fredrik Brag, CEO, and co-founder of Median Technologies, said:
    “During the first three quarters of 2023, we made significant strides regarding iBiopsy®.
  • These are key milestones in our roadmap to obtain marketing authorizations for our Software as Medical Device for the US and European markets.
  • Median is poised to play a pivotal role to help significantly reduce the lung cancer mortality rate through more effective diagnosis of early-stage patients.

Median Technologies’ Global iCRO Team to participate in the 2023 ESMO Congress, Oct 20 – 24, 2023, Madrid, Spain

Retrieved on: 
Monday, October 16, 2023
Oncology, Medical Devices, Health, Health Technology, Pharmaceutical, Biotechnology, Congress, European Society for Medical Oncology, ESMO, Cave rescue, Nightclub

Median Technologies (ALMDT:PA) announced today that the Company will be participating in the prestigious 2023 European Society for Medical Oncology (ESMO) Congress, set to take place in Madrid, Spain (venue: IFEMA).

Key Points: 
  • Median Technologies (ALMDT:PA) announced today that the Company will be participating in the prestigious 2023 European Society for Medical Oncology (ESMO) Congress, set to take place in Madrid, Spain (venue: IFEMA).
  • The event, scheduled from October 20th to 24th, promises to be a remarkable platform for the exchange of groundbreaking insights and cutting-edge developments in the field of oncology.
  • “As a testament to the commitment of advancing cancer care worldwide, we will be participating with the goal of sharing our expertise in clinical trial imaging as well as advanced, AI-powered insights,” said Nicolas Dano, Chief Operating Officer, iCRO, of Median Technologies.
  • “We are thrilled to be bringing together for the first time our expert teams spanning across the Europe, United States, and China, and invite all attendees to visit booth #552 to engage with our experts and experience firsthand the impact of our pioneering solutions.”
    More about the ESMO congress: https://www.esmo.org/meeting-calendar/esmo-congress-2023

Imaging Endpoints Appoints Manish Sharma, MD as Chief Scientific Officer

Retrieved on: 
Wednesday, September 6, 2023
Metadata, Bureau of Oceans and International Environmental and Scientific Affairs, Cave rescue, Big data, Deep learning, Clinical trial, NDA, Cure, Doctor of Philosophy, Aptitude, Patient, Growth, ANDA, Research, IND, ChromeOS, Data science, Medical imaging, MD

SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.
  • Dr Sharma, a radiologist with over 20 years of extensive experience in clinical research, medical imaging, and data science, joins Imaging Endpoints with a proven track record of excellence.
  • "Manish's extensive expertise and innovative approach align perfectly with our vision to 'Connect Imaging to the Cure,'" said Ronald Korn, MD, PhD, Chief Medical Officer and Founder of Imaging Endpoints.
  • Dr. Sharma will oversee Medical and Scientific Affairs as well as Research and Development at Imaging Endpoints.

Imaging Endpoints Appoints Manish Sharma, MD as Chief Scientific Officer

Retrieved on: 
Wednesday, September 6, 2023
Metadata, Bureau of Oceans and International Environmental and Scientific Affairs, Cave rescue, Big data, Deep learning, Clinical trial, NDA, Cure, Doctor of Philosophy, Aptitude, Patient, Growth, ANDA, Research, IND, ChromeOS, Data science, Medical imaging, MD

SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.
  • Dr Sharma, a radiologist with over 20 years of extensive experience in clinical research, medical imaging, and data science, joins Imaging Endpoints with a proven track record of excellence.
  • "Manish's extensive expertise and innovative approach align perfectly with our vision to 'Connect Imaging to the Cure,'" said Ronald Korn, MD, PhD, Chief Medical Officer and Founder of Imaging Endpoints.
  • Dr. Sharma will oversee Medical and Scientific Affairs as well as Research and Development at Imaging Endpoints.

Median Technologies Reports Its Business Activity for the First Half of 2023 and Announces the First Step of Its Refinancing Plan

Retrieved on: 
Wednesday, July 12, 2023
Data Management, Biotechnology, Technology, Other Health, Health, Biometrics, Oncology, Health Technology, Medical Devices, Software, Artificial Intelligence, Medical device, CE, Euronext Growth, US, EU, Cave rescue, LCS, Bank statement, BofA Securities, Clinical trial, Lung cancer screening, Fruit, Burn, European Investment Bank, Convertible, MRMC, CSF, EIB, FDA, Pharmaceutical industry, LP

Median Technologies (Euronext Growth - ALMDT) reports today its business indicators for the first half of 2023 for the iCRO activity (non-audited figures) and the iBiopsy® activity.

Key Points: 
  • Median Technologies (Euronext Growth - ALMDT) reports today its business indicators for the first half of 2023 for the iCRO activity (non-audited figures) and the iBiopsy® activity.
  • "When it comes to our iBiopsy® LCS CADe/CADx Software as Medical Device, the design of our pivotal validation plan has been finalized since March 2023.
  • In Q2 2023, the Company's revenue stands at €5.8M, up by 3.6% from Q1 2023 and 13.7% compared to Q4 2022 revenue.
  • As at June 30, 2023, Median Technologies' cash and cash equivalents stand at €8.3M, compared to €13.1M at March 31, 2023, i.e.

Median Technologies Reports Full-year 2022 Results and Business Indicators for the First Quarter Of 2023

Retrieved on: 
Thursday, April 20, 2023
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Medical device, Malignancy, Euronext Growth, BofA Securities, Cave rescue, LCS, ECR, Lab, Bank statement, COVID-19, Lung cancer screening, Cancer, Lung cancer, Biomarker, European Congress of Radiology, Liver cancer, ASCO, Bent Image Lab, 2023 International Conference on Climate Resilient Pakistan, American Society of Clinical Oncology, Patient, Artificial intelligence, Diagnosis, AI, EIB, FDA, European Investment Bank, Society, Conference, Cryptocurrency, Pharmaceutical industry, Medical imaging, Median

Median Technologies (Euronext Growth - ALMDT) (Paris;ALMDT) whose Board of Directors met on April 19, 2023 to approve the consolidated financial statements for the financial year ending December 31, 2022, today announces its full-year results for 2022 and business indicators (unaudited) for the first quarter of 2023.

Key Points: 
  • Median Technologies (Euronext Growth - ALMDT) (Paris;ALMDT) whose Board of Directors met on April 19, 2023 to approve the consolidated financial statements for the financial year ending December 31, 2022, today announces its full-year results for 2022 and business indicators (unaudited) for the first quarter of 2023.
  • In the first quarter of 2023, we achieved revenue of €5.6 million, with an order backlog of €62 million at March 31.
  • In March 2023 , Median Technologies presented new results for the performance of its iBiopsy® LCS CADe/CADx SaMD.
  • On January 19, 2023 , Median reported business indicators for 2022 and now confirms the following audited figures:
    An order backlog at December 31, 2022 of €60.8 million;
    Cash and cash equivalents of €21.5 million at December 31, 2022.

Median Technologies Announces 2022 Revenue of €23.8 Million, up 16%, and an Order Backlog of €60.8 Million

Retrieved on: 
Thursday, January 19, 2023
Technology, Medical Devices, FDA, Biotechnology, Other Health, Radiology, Health, Artificial Intelligence, Oncology, Cave rescue, Intelligence cycle, LCS, ASCO, Biomarker, Collection, American Society of Clinical Oncology, Bent Image Lab, Marketing, Lab, Patient, Intelligence, Research, HIV disease progression rates, Artificial intelligence, Society, Medical device, Medical imaging

Median Technologies (ALMDT:PA) announces its revenue level for the full year 2022.

Key Points: 
  • Median Technologies (ALMDT:PA) announces its revenue level for the full year 2022.
  • As of December 31, 2022, Median Technologies’ revenue was €23.8 million, a 16% increase compared to the 2021 level.
  • The order backlog5 stood at €60.8 million on December 31, 2022, up €2.8 million relative to December 31, 2021.
  • As of December 31, 2022, cash and cash equivalents stood at €21.5 million, compared to €39 million as of December 31, 2021.

Median Technologies to Speak at the Radiological Society of North America (RSNA) 2022 Annual Meeting, Nov. 27 - Dec 1, Chicago, IL, USA, With Three Presentations

Retrieved on: 
Tuesday, November 22, 2022
Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Medical Devices, Technology, Other Health, AI, BPI, Patient, Cancer, Cave rescue, Exhibition, SME, Artificial intelligence, Diagnosis

Medians teams will be available at booth #4849, Level 3 South Hall (AI showcase) for the duration of the industry exhibition (Nov 27- 30).

Key Points: 
  • Medians teams will be available at booth #4849, Level 3 South Hall (AI showcase) for the duration of the industry exhibition (Nov 27- 30).
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.
  • This is how we are helping to create a healthier world.
  • Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext PEA-PME 150 index and has been awarded the Euronext European Rising Tech label.